Yellow Fever Vaccine

Persons With Diseases of the Thymus Should Consider Alternatives to Receiving Yellow Fever Vaccine CDC investigators have identified diseases of the thymus as a possible risk factor for severe complications following yellow fever vaccine. [click for more info]. Barwick R. History of thymoma and yellow fever vaccination. Lancet 2004; 364(9438):936.
Evidence of rare, severe adverse reactions to 17D Yellow Fever Vaccine Three articles and a commentary in the July 14, 2001 issue of the Lancet provide data on 7 people who developed severe yellow-fever like illness following yellow fever vaccines. Yellow fever vaccine is a live attenuated viral vaccine. Investigators have speculated that persons over 55 or 60 years of age may be at increased risk of this rare complication.
Marianneau P, Georges-Courbot M, Deubel V. Rarity of adverse effects after 17D yellow-fever vaccination (commentary) Lancet 2001 Jul 14;358(9276):84-5. [link to pubmed abstract]
Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001 Jul 14;358(9276):91-7. [link to pubmed abstract]
Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lance. 2001 Jul 14;358(9276):98-104. [link to pubmed abstract]
Chan RC, Penney DJ, Little D, et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001 Jul 14;358(9276):121-2. [link to pubmed abstract]
Comprehensive Yellow Fever Vaccination Requirements for Travelers (from CDC).
Maps of 2005 Endemic areas in Africa and South/Central America.

This page was last updated on January 23, 2008